Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...

Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” ...

Researchers at the University of Toronto have invented a new method that uses DNA sequencing to measure metabolites. This ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Researchers at the University of Toronto have invented a new method that uses DNA sequencing to measure metabolites. This ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 16.38%, which has investors questioning if this is right time to buy.

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

Ginkgo Bioworks Holdings, Inc. (DNA) shares ended the last trading session 14.5% higher at $16.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...

Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of Evaxion Biotech A/S in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst S.